Business Context and Reporting Period
Company: Alzamend Neuro, Inc. (ALZN)
Filing Type: Form 8-K (Current Report)
Date of Report: March 22, 2024
Reporting Period: Events occurring on March 21, 2024, and March 1, 2024.
Context: The Company is an emerging growth company incorporated in Delaware. This filing reports material amendments to existing financial instruments to ensure proper equity classification under accounting standards.
Key Financial Metrics
This filing is a current report regarding legal and contractual amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes Versus Prior Period
The filing details specific amendments to two instruments previously issued to Ault Lending, LLC:
- Warrant Amendment: On March 21, 2024, the Company amended a warrant issued on January 31, 2024. Section 3(d) was revised to remove language that could have prevented the warrant from being classified as equity.
- Series B Preferred Stock Amendment: On March 21, 2024, the Company filed a Certificate of Amendment to the Series B Convertible Preferred Stock designations (originally amended on March 1, 2024). Sections 5(b) and 5(c) were deleted to remove language regarding liquidation preference rights that could have prevented the stock from being classified as equity.
Guidance, Outlook, and Risks
Management Commentary: Management executed these amendments specifically to address accounting classification concerns. The changes were made to ensure that both the warrant and the Series B Convertible Preferred Stock are classified as equity rather than liabilities.
Risks and Contingencies: The primary risk addressed was the potential misclassification of these securities as liabilities, which could negatively impact the Company's balance sheet and financial ratios. No other risks, guidance, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the full text of the Warrant Amendment Agreement (Exhibit 4.1) to confirm the specific language removed from Section 3(d).
- Review the Certificate of Amendment to the Series B Preferred Stock (Exhibit 3.1) to confirm the deletion of Sections 5(b) and 5(c).
- Confirm with the Company's most recent 10-Q or 10-K how these amendments impact the classification of liabilities versus equity on the balance sheet.
- Check for any subsequent filings regarding the impact of these amendments on the Company's financial statements.